Stockwinners Market Radar for June 18, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EDT Cathie Wood's ARK Investment buys 163K shares of PagerDuty today

19:50 EDT Bluejay Diagnostics Inc trading halted, news pending

18:57 EDT CoStar Group names Chris Lown as new CFO - Earlier today, the company announced: "CoStar Group announced the appointment of Christian M. Lown as Chief Financial Officer effective July 1, 2024. Lown will join CoStar Group from Fortune 500-ranked home loan giant Freddie Mac, where he serves as Executive Vice President and Chief Financial Officer until June 28, 2024. He will report to Andy Florance, Founder and Chief Executive Officer of CoStar Group."

18:21 EDT AbbVie: FDA approves SKYRIZI for ulcerative colitis - AbbVie announced the U.S. FDA has approved SKYRIZI for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease.3 SKYRIZI is now approved for four indications across immune-mediated inflammatory diseases.

17:45 EDT Equity Commonwealth announces $150M buyback authorization - Equity Commonwealth announced that its Board of Trustees authorized the repurchase, from July 1, 2024 through June 30, 2025, of up to an additional $150 million of its outstanding common shares under the company's existing share repurchase program. The company still has $93 million remaining under its prior authorization that expires on June 30, 2024. Year-to-date through June 18, 2024 the company has not repurchased any shares.

17:32 EDT ArrowMark Financial reports estimated NAV $21.76 as of May 31 -

17:21 EDT KB Home sees Q3 housing revenue $1.65B-$1.75B - Sees Q3 average selling price around $482,000. Sees Q3 operating margin 10.8%-11.4%. Sees Q3 housing gross profit margin 21.0%-21.4%. Comments taken from Q2 earnings conference call.

17:15 EDT KB Home says raising minimum buyback level to $250M

17:08 EDT KB Home CEO says build times are normalizing - Says Q2 saw indicators that reinforced higher rate of demand. Comments taken from Q2 earnings conference call.

16:44 EDT Lockheed Martin selected by NASA in $2.27B contract - NASA, on behalf of the National Oceanic and Atmospheric Administration, has selected Lockheed Martin to build the spacecraft for NOAA's Geostationary Extended Observations satellite program. This cost-plus-award-fee contract is valued at approximately $2.27 billion. It includes the development of three spacecraft as well as four options for additional spacecraft. The anticipated period of performance for this contract includes support for 10 years of on-orbit operations and five years of on-orbit storage, for a total of 15 years for each spacecraft. The work will take place at Lockheed Martin's facility in Littleton and NASA's Kennedy Space Center in Florida. The GeoXO constellation will include three operational satellites - east, west and central. Each geostationary, three-axis stabilized spacecraft is designed to host three instruments. The centrally-located spacecraft will carry an infrared sounder and atmospheric composition instrument and can also accommodate a partner payload. Spacecraft in the east and west positions will carry an imager, lightning mapper, and ocean color instrument. They will also support an auxiliary communication payload for the NOAA Data Collection System relay, dissemination, and commanding.

16:31 EDT NeueHealth discloses NYSE listing compliance notice - NeueHealth announced that on June 12, 2024, the Company received a written notice from the New York Stock Exchange that the Company no longer satisfies the continued listing standards set forth under Section 802.01B of the NYSE's Listed Company Manual. The notice cited that the Company's average market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, the Company's last reported stockholders' equity was less than $50 million. As of June 11, 2024, the 30 trading-day average market capitalization was approximately $49.7 million, and the company reported a stockholders' deficit. The Company's preferred stock, which had a value of $920.4 million as of March 31, 2024, is excluded from the average market capitalization as calculated by the NYSE. This notice does not impact the Company's business operations.

16:20 EDT Cara Therapeutics announces 70% workforce reduction - In a regulatory filing, Cara Therapeutics disclosed that on June 14, the Board of Directors of the company approved a streamlined operating plan exploring strategic alternatives focused on maximizing shareholder value after the company announced its decision to discontinue the clinical program in notalgia paresthetica following the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with NP on June 12. In connection with the streamlined operating plan, the Board of Directors also approved a reduction in the company's workforce by approximately 70%, which the company expects to substantially complete by June 30. The company anticipates recognizing approximately $2.6M in total charges in connection with the reduction in force, which costs are expected to be substantially recognized in the second and third quarter of 2024. These charges will consist primarily of one-time cash charges for termination benefits. The charges the company expects to incur in connection with this reduction in workforce are subject to a number of assumptions, risks and uncertainties, and actual results may materially differ. The company may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, these actions.

16:14 EDT KB Home up 4% after Q2 earnings beat at $70.68

16:12 EDT KB Home narrows FY24 housing revenue view to $6.7B-$6.9B from $6.5B-$6.9B - Sees FY24 average selling price in the range of $485,000 to $495,000 and Homebuilding operating income as a percentage of revenues in the range of 11.0% to 11.4%.

16:07 EDT Biolase announces delisting from Nasdaq - Biolase announced that the company received a notice from Nasdaq that it has determined to delist the shares of the company's common stock from The Nasdaq Stock Market. The delisting is a result of failure to satisfy the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) and failure to comply with Nasdaq's $2,500,000 minimum stockholders' equity requirement for continued listing or any of the alternative requirements in Listing Rule 5550(b). Suspension of trading in the company's common stock on the Nasdaq exchange will be effective at the open of trading on June 20, 2024.

16:01 EDT Akili announces FDA authorization of EndeavorOTC - Akili announced U.S. Food and Drug Administration clearance of EndeavorOTC as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder. Delivered through an engaging video game experience, EndeavorOTC is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. EndeavorOTC is Akili's second digital ADHD therapeutic product to receive FDA authorization, and is the only FDA-authorized digital therapeutic for ADHD available without a prescription. EndeavorOTC is currently available in the United States on the Apple App Store for iOS and the Google Play Store for Android mobile devices. "This FDA authorization of EndeavorOTC positions it as a scientifically and clinically validated digital therapy for adult ADHD patients, and we're incredibly proud of pioneering a new tier of digital medicine," said Matt Franklin, Chief Executive Officer at Akili. "This is the culmination of years of clinical studies and the collective effort of scores of technical, scientific, clinical, and regulatory professionals. We are particularly grateful to the patients who participated in the study that made this clearance possible."

15:44 EDT United States files Fair Housing Act lawsuit against Toll Brothers - Damian Williams, the United States Attorney for the Southern District of New York, announced that the United States has filed a federal Fair Housing Act, or "FHA," lawsuit against Toll Brothers and Toll Brothers Realty Trust, relating to their failure to design and construct new apartment buildings so as to be accessible to persons with physical disabilities. The lawsuit also names certain Toll Brothers affiliates as well as other entities that participated in the design or construction of these residential complexes, as well as a condominium association whose cooperation is essential to ensure retrofits. Upon filing suit, the United States also submitted to the Court a proposed consent decree with LENDLEASE, which participated in the design and construction of one such building. This settlement is subject to the review and approval of the U.S. District Judge assigned to the case. Reference Link

15:21 EDT Desktop Metal paused for volatility after jumping 35% to $4.94

14:58 EDT Merck treatment of gastric cancer granted FDA orphan designation - The FDA granted orphan designation to Merck's recombinant humanized IgG1 anti-TROP2 monoclonal antibody conjugated to a topoisomerase I inhibitor as a treatment of gastric cancer, including cancer of the gastroesophageal junction, according to a post to the agency's website. Reference Link

14:32 EDT Snap unveils new AR experiences powered by GenAI - "At Snap, we believe in building and advancing technology that empowers our global community to express themselves and bring their creativity to life. So today, we're unveiling new AR experiences powered by GenAI for Snapchatters and our AR developer community. We're previewing Snap's real-time image model that can instantly bring your imagination to life in AR. This early prototype makes it possible to type in an idea for a transformation and generate vivid AR experiences in real time.This milestone of running GenAI models in real-time on mobile devices is made possible by our team's breakthroughs to optimize faster, more performant GenAI techniques. Our team of researchers and engineers is constantly innovating to make GenAI faster and lighter, so our Snapchat community can create and communicate with their friends on the go. Our GenAI techniques power Bitmoji Backgrounds, Chat Wallpapers, Dreams, AI Pets and of course, our AI Lenses....We're also introducing a new GenAI Suite to our AR authoring tool Lens Studio, enabling AR creators to generate custom ML models and assets to power their Lenses. ...This update empowers AR creators, developers, and teams with new tools to personalize their development workflow, so they can extend the capabilities of Lens Studio and build more complex projects...We can't wait for our community to try these new tools and explore their creative potential," said Snap in part earlier, in a blog post. Reference Link

14:16 EDT FDA issues warning letter to Dollar Tree over lead-contaminated product - According to a warning letter the Food and Drug Administration posted on its website, Dollar Tree has continued to sell WanaBana apple cinnamon fruit puree pouches tainted with "extremely high" levels of lead, long after the product recall. The letter reads, "laboratory analysis of multiple lots of WanaBana Apple Cinnamon Fruit Puree pouches, including finished product samples collected from Dollar Tree stores, detected extremely high concentrations of lead... On October 29, 2023, Wanabana USA initiated a voluntary recall of all WanaBana Apple Cinnamon Fruit Puree pouches... Subsequent recall audit checks of your Dollar Tree and Family Dollar/Dollar Tree combination stores revealed that you continued to offer the recalled WanaBana Apple Cinnamon Fruit Puree pouches on store shelves well after the recall was initiated, despite FDA's numerous attempts to bring this serious issue to your attention." Reference Link

14:02 EDT DermTech files for voluntary chapter 11 protection, implements 20% RIF - DermTech filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the company's strategic alternatives review process. Currently, the company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test DMT , while simultaneously conducting a process to sell substantially all of its assets. Through the bankruptcy process, the company intends to safeguard the interest of stakeholders and maximize the value of its assets. ...Alongside the chapter 11 filings, the company also implemented a reduction in force RIF to significantly reduce expenses associated with its current operations to preserve cash. This RIF resulted in an immediate workforce reduction of approximately 15 employees approximately 20% of the Company's workforce with potential additional reductions of DermTech's workforce in the future.

13:38 EDT Blue World Acquisition Corp trading halted, volatility trading pause

13:03 EDT Tenaris ordered by court to pay indemnification to CSN - Tenaris S.A. (TS) announced that the Brazilian Superior Court of Justice, or SCJ, resolved that Tenaris's subsidiary Confab and certain subsidiaries of Tenaris's affiliate Ternium (TX), all of which compose the T/T Group under the Usiminas shareholders agreement, should pay Companhia Siderurgica Nacional, or CSN (SID), an indemnification in connection with the acquisition by the T/T Group of a participation in Usiminas in January 2012. "CSN and various entities affiliated with CSN had filed a lawsuit in Brazil against the T/T Group, alleging that, under applicable Brazilian laws and rules, the acquirers were required to launch a tag-along tender offer to all non-controlling holders of Usiminas ordinary shares for a price per share equal to 80% of the price per share paid in such acquisition. On September 23, 2013, the first instance court dismissed the CSN lawsuit, and on February 8, 2017, the court of appeals upheld the first instance court decision. On March 7, 2023, the SCJ rejected CSN's appeal by majority vote. The composition of the SCJ panel in charge of the case subsequently changed and CSN made several submissions in connection with the SCJ decision, including a motion for clarification with the SCJ that challenged the merits of its earlier decision. At today's session, the SCJ completed its voting on CSN's motion for clarification and reversed, by majority vote, its March 7, 2023 decision, and granted CSN an indemnification, with CSN being allowed to retain ownership of the Usiminas ordinary shares it currently owns. Depending on how the indemnification is calculated by other courts, and assuming monetary adjustment and interest through May 31, 2024, the potential aggregate indemnification payable by Confab could reach up to BRL942 million, or approximately $180M. The Company continues to believe that all of CSN's claims and allegations are groundless and without merit, as confirmed by several opinions of Brazilian legal counsel, two decisions issued by the Brazilian securities regulator in February 2012 and December 2016, the first and second instance court decisions and the March 7, 2023 SCJ decision referred to above. The Company also believes that today's SCJ decision on CSN's motion for clarification is contrary to applicable substantive and procedural law. Accordingly, once the SCJ written votes are made available, Confab will file all available motions and appeals against the SCJ decision," Tenaris stated.

12:53 EDT HP Enterprise introduces new AI and hybrid cloud programs - Hewlett Packard Enterprise (HPE) announced a new AI enablement program, in collaboration with Nvidia (NVDA), designed to boost profitability and deliver new revenue streams for partners. "The program offers new competencies and additional resources across AI, compute, storage, networking, hybrid cloud, sustainability, as well as enhanced HPE GreenLake offerings and capabilities. HPE announced, as part of its new NVIDIA AI Computing by HPE portfolio, a new AI partner strategy with NVIDIA aimed at driving greater innovation and more opportunities to leverage HPE's pioneering edge-to-cloud portfolio," Hewlett Packard Enterprise stated.

12:42 EDT Logistic Properties of The Americas trading resumes

12:25 EDT Nuvei obtains shareholder approval for going private transaction with Advent - Nuvei Corporation announced that, at the special meeting of the Company's shareholders held on June 18, 2024, Shareholders approved the special resolution approving the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act involving the Company and Neon Maple Purchaser, a newly-formed entity controlled by Advent International, L.P. Pursuant to the Arrangement, the Purchaser will acquire all of the issued and outstanding subordinate voting shares and multiple voting shares of the Company. The Shares that are not held by Philip Fayer, certain investment funds managed by Novacap Management and Caisse de depot et placement du Quebec. will be acquired for a price of $34.00 in cash per Share. Each of the Rollover Shareholders has agreed to sell all of their Shares to the Purchaser in exchange for consideration consisting of a combination of cash and shares in the capital of the Purchaser or an affiliate thereof. Following completion of the Arrangement, Philip Fayer, Novacap and CDPQ are expected to hold or exercise control or direction over, directly or indirectly, approximately 24%, 18% and 12%, respectively, of the common equity in the resulting private company.

12:11 EDT Advantage Solutions to sell Jun Group for $185M - Advantage Solutions announced has entered into an agreement to sell its digital advertising platform Jun Group to Verve Group SE, a Swedish digital advertising company formerly known as Media and Games Invest SE. Gross proceeds from the sale are expected to be approximately $185 million, the majority of which will be received in cash at closing. The transaction is expected to close in the third quarter, subject to regulatory and other approvals. As part of the agreement, Verve will pay Advantage approximately $130 million in cash at close, plus two additional installments paid 12 months and 18 months post-close to complete the deal. Advantage plans to use the majority of initial proceeds to pay down debt and reinvest in the business. The company remains committed to reducing its net leverage ratio to less than 3.5 times. Jun Group, which Advantage acquired in 2018, is a technology company that powers digital media campaigns on digital platforms, including smart phones, tablets and desktop computers. While Jun Group provides some services to retailers and consumer-packaged goods companies, many of its customers - including publishers and health care companies - are distinct from Advantage's core customer base.

12:04 EDT Jumia Technologies falls -10.6% - Jumia Technologies is down -10.6%, or -$1.00 to $8.41.

12:03 EDT Virgin Galactic falls -14.4% - Virgin Galactic is down -14.4%, or -$1.68 to $10.02.

12:01 EDT Caesars completes acquisition of Michigan iGaming operations from Wynn Resorts - Caesars Entertainment (CZR) announced the closing of the previously announced acquisition of the operations of WynnBET's (WYNN) Michigan iGaming business and long-term extension of iGaming market access rights with the Sault Ste. Marie Tribe of Chippewa Indians. Caesars will assume operations on the existing platform under the WynnBET brand with no anticipated interruption to the customer experience. This transaction further enhances our iCasino Net Revenue growth in an EBITDA accretive manner. Caesars Entertainment will announce a new online casino brand and the transition of the WynnBET iCasino operations to Caesars' Michigan iGaming Platform in the second half of 2024, pending regulatory approvals. "Caesars Entertainment would like to thank the Sault Ste. Marie Tribe of Chippewa Indians and the Michigan Gaming Control Board for their collaboration through this process," said Eric Hession, President of Caesars Digital.

12:00 EDT La-Z-Boy rises 17.5% - La-Z-Boy is up 17.5%, or $5.95 to $40.04.

11:44 EDT Companhia Siderugica Hacional trading resumes

11:37 EDT Lennar down 4% as earnings call continues - Shares of Lennar are down $6.26, or 4%, to $150.25 as the company's Q2 earnings conference call continues.

11:33 EDT Lennar has made 'substantial' progress over last 90 days on land spinoff

11:29 EDT Brazilian court orders Ternium to pay indemnification to CSN - Ternium S.A. (TX) announced that the Brazilian Superior Court of Justice, or SCJ, resolved that Ternium's subsidiaries Ternium Investments and Ternium Argentina, and Tenaris's subsidiary Confab, all of which compose the T/T Group under the Usiminas shareholders agreement, should pay Companhia Siderurgica Nacional, or CSN (SID) an indemnification in connection with the acquisition by the T/T Group of a participation in Usiminas in January 2012. "CSN and various entities affiliated with CSN had filed a lawsuit in Brazil against the T/T Group, alleging that, under applicable Brazilian laws and rules, the acquirers were required to launch a tag-along tender offer to all non-controlling holders of Usiminas ordinary shares for a price per share equal to 80% of the price per share paid in such acquisition. On September 23, 2013, the first instance court dismissed the CSN lawsuit, and on February 8, 2017, the court of appeals upheld the first instance court decision. On March 7, 2023, the SCJ rejected CSN's appeal by majority vote. The composition of the SCJ panel in charge of the case subsequently changed and CSN made several submissions in connection with the SCJ decision, including a motion for clarification with the SCJ that challenged the merits of its earlier decision. At today's session, the SCJ completed its voting on CSN's motion for clarification and reversed, by majority vote, its March 7, 2023 decision and granted CSN an indemnification, with CSN being allowed to retain ownership of the Usiminas ordinary shares it currently owns. Depending on how the indemnification is calculated by other courts, and assuming monetary adjustment and interest through May 31, 2024, the potential aggregate indemnification payable by Ternium Investments and Ternium Argentina could reach up to BRL3.2 billion, or approximately $0.6B and BRL1.1 billion, or approximately $0.2B, respectively. The Company continues to believe that all of CSN's claims and allegations are groundless and without merit, as confirmed by several opinions of Brazilian legal counsel, two decisions issued by the Brazilian securities regulator in February 2012 and December 2016, the first and second instance court decisions and the March 7, 2023 SCJ decision referred to above. The Company also believes that today's SCJ decision on CSN's motion for clarification is contrary to applicable substantive and procedural law. Accordingly, once the SCJ written votes are made available, Ternium Investments and Ternium Argentina will file all available motions and appeals against the SCJ decision," Ternium stated.

11:06 EDT FEVO announces Shift4 as preferred payments, POS solution for music partners - FEVO announced that Shift4 will act as its preferred payment processor for all music festivals and General Admission events. The partnership will allow FEVO to support venue, touring and festival clients with seamless payment and checkout solutions across online transactions, mobile ordering, QR-code ticket sales and on-site GA sales - all features that have helped Shift4 become a global leader in payment processing and commerce technology.

11:03 EDT JetBlue includes free carry-on bag in Blue Basic fare - JetBlue is elevating the value of its Blue Basic fare by including a free carry-on bag for customers flying beginning September 6, 2024, regardless of purchase date. Previously, customers who wished to bring a carry-on bag would need to purchase one of JetBlue's other fare options or purchase an Even More Space seat.

10:33 EDT Home Depot completes acquisition of SRS Distribution - The Home Depot has completed the acquisition of SRS Distribution, Inc. for a total enterprise value of approximately $18.25B. SRS is a leading residential specialty trade distribution company across several verticals serving the professional roofer, landscaper and pool contractor. The agreement to acquire SRS was announced on March 28, 2024. The acquisition will increase the company's total addressable market to approximately $1T, an increase of approximately $50B. The combination of the two businesses will accelerate The Home Depot's growth with the residential professional customer. SRS complements The Home Depot's capabilities and enables the company to better serve the complex purchase occasion, while also establishing The Home Depot as a leading specialty trade distributor across multiple verticals.

10:31 EDT Warner Bros. Discovery names Chief Communications and Public Affairs Officer - Warner Bros. Discovery (WBD) announced that Robert Gibbs has been appointed Chief Communications and Public Affairs Officer. In this newly created role, he will oversee WBD's corporate and business communications as well as public affairs. Gibbs will officially assume the role on August 5 and report to David Zaslav, Chief Executive Officer. Gibbs most recently served as a Partner at Bully Pulpit International, a strategic communications, public affairs, and corporate reputation advisory firm, and from 2015 to 2019, Gibbs served as the Executive Vice President for Corporate Relations and Global Chief Communications Officer for McDonald's (MCD), the company noted.

10:09 EDT Ahold Delhaize USA, Kellanova, Bartlet announce regenerative agriculture pilot - Ahold Delhaize USA (ADRNY) has announced a partnership with global snacking leader Kellanova (K) and North American agribusiness, Bartlett, to reduce Scope 3 greenhouse gas emissions from wheat farming across the value chain. This collaboration aims to decrease Scope 3 emissions, improving farm and supply chain resiliency. The pilot program, which is expected to kick off this summer, will leverage financial investments from Ahold Delhaize USA, Kellanova and Bartlett to support the adoption of regenerative agricultural practices among wheat farmers in North Carolina. The wheat harvested and milled from these farms will be used alongside conventionally grown wheat to produce Kellanova's iconic Cheez-It and Club(R) crackers. These products will be sold at the local brand stores of Ahold Delhaize USA in 2025.

10:06 EDT Trust Stamp launches Identity Hub on AWS Marketplace - Trust Stamp announced that the Identity Hub has launched on the AWS Marketplace. The AWS Marketplace offers streamlined procurement, flexible pricing and centralized control and governance including the ability for customers to procure and pay for Trust Stamp's software through their existing AWS account.

10:05 EDT Li-Cycle rises 10.8% - Li-Cycle is up 10.8%, or 50c to $5.14.

10:03 EDT Cosmos enters agreement to acquire remaining rights to WIPO-filed patent - Cosmos Health has entered into an agreement to acquire all remaining rights arising from the patent filed with the World Intellectual Property Organization under reference code PCT/EP2023/071865. This follows the agreement announced on December 7, 2023, where Cosmos Health had acquired 60% of the rights. One of the sellers, the prestigious National Hellenic Research Foundation, founded in 1958, is among the largest research centers in Greece. As a non-profit organization supervised by the General Secretariat for Research and Innovationof the Ministry of Development, the foundation has played a crucial role in the development phase. It will continue to support Cosmos Health as it transitions to sole ownership and pursues its commercial objectives.

10:02 EDT Veris Residential falls -5.8% - Veris Residential is down -5.8%, or -88c to $14.31.

10:00 EDT Virgin Galactic falls -12.6% - Virgin Galactic is down -12.6%, or -$1.48 to $10.22.

09:53 EDT Chegg rises 17.8% - Chegg is up 17.8%, or 47c to $3.08.

09:50 EDT NextEra Energy falls -3.8% - NextEra Energy is down -3.8%, or -$2.74 to $69.57.

09:47 EDT Studio City falls -9.7% - Studio City is down -9.7%, or -70c to $6.55.

09:39 EDT Neurogene announces first patient dosed in high-dose cohort of NGN-401 - Neurogene announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for female pediatric patients with Rett syndrome, and high-dose NGN-401 has been well-tolerated following dosing in May 2024. The Company also provided an update on interim safety data on the first three patients in the low-dose cohort during the IRSF ASCEND 2024 Rett Syndrome National Summit, which shows that NGN-401 has continued to have a favorable safety profile with no new treatment-related adverse events.

09:31 EDT PURE Bioscience enters international supply, license agreement with AgroVet - PURE Bioscience and AgroVet Alliance have entered into a multi-year international supply and license agreement for the purchase and selling of SDC products under special terms and conditions.

09:24 EDT Tyler Technologies launches electronic lien, title service for New Jersey - Tyler Technologies, in partnership with Champ Titles, and the New Jersey Motor Vehicle Commission, has launched a new electronic lien and title service for vehicle titling. Driven by recently passed legislation, the Motor Vehicle Commission was tasked with implementing a solution that allows electronic submission of required forms and fees. The legislation not only requires the New Jersey Motor Vehicle Commission to implement an electronic lien and title service but also mandates that all lienholders in New Jersey participate in this new electronic program, unless they are otherwise exempt. The new system, whose formal pilot launched in January, allows lienholders financing vehicles in New Jersey to communicate in real time with the New Jersey Motor Vehicle Commission and eliminates the need for those lienholders to hold, manage, and ship secure paper titles.

09:23 EDT Nortech Systems appoints Sen to board of directors - Nortech Systems announced the addition of Debarati Sen to the Company's Board of Directors. Sen is currently the Group President for HMTX Industries.

09:17 EDT Shuttle Pharmaceuticals appoints Timothy Lorber as CFO - Shuttle Pharmaceuticals Holdings announced the appointment of Timothy Lorber, CPA, as the company Chief Financial Officer. The company's current Chief Financial Officer, Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and will assume the Vice President, Regulatory position on a full-time basis.

09:16 EDT Applied DNA Sciences partners with GenXys Health Care Systems - Applied DNA Sciences announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, will utilize the GenXys Health Care Systems suite of clinical decision support software for interpretation and reporting of ADCL's New York State Department of Health-approved TR8 pharmacogenomic test. The partnership is designed to improve patient outcomes and reduce healthcare costs through a data-driven approach that relates an individual's genetic factors to potential responses to prescription drugs. Applied DNA's TR8 PGx assay simultaneously interrogates 120 genetic variants across more than 30 genes that have been shown to affect the rate with which the body absorbs, activates, distributes, and metabolizes drugs, which can, in turn, impact the efficacy and safety of medications. The genetic variations targeted by TR8 PGx are relevant to a broad range of medicines, including cardiac, pain management, cancer, and psychiatric drugs.

09:15 EDT Lexaria Bioscience awards CRO contract for DehydraTECH GLP-1 human study - Lexaria Bioscience has now hired a contract research organization to oversee execution of the Company's 12-week chronic study GLP-1-H24-4 which will evaluate various DehydraTECH-GLP-1 formulations and other treatments with efficacy objectives of weight loss, blood sugar reduction, and more. Study preparations with the CRO have commenced pursuant to an initial start-up agreement under which a number of activities will occur such as full clinical protocol design and writing in consultation with medical experts, regulatory authority submissions, and data management planning. The Study will be conducted using a number of clinical investigational sites in Australia as a registrational Phase 1b study within Australian clinical regulatory authority regulations. Upon completion, the Study is expected to be equally regarded as a Phase 1b registrational study by the U.S. Food and Drug Administration.

09:11 EDT Sintx Technologies announces exploration of potential strategic options - SINTX Technologies announced that its Board of Directors has initiated a process to explore potential strategic options for the Company. SINTX has multiple business lines focused on technical materials, with manufacturing and R&D sites located in Salt Lake City and Millersville, MD. In addition to its FDA-approved silicon nitride ceramic spinal fusion devices, the Company has developed ceramic-polymer composites, a novel technology that addresses other medical devices, such as implants for lower extremity fusion. Based on extensive peer-reviewed published data, the key advantages of the Company's proprietary medical-grade silicon nitride include its proven biocompatibility, inherent resistance to bacteria and viruses, bone cell stimulation, and ease of radiographic imaging. More recently, the Company's femoral head technology has attracted renewed interest from several global partners. The Company's silicon nitride is also being utilized in several aerospace engine applications, with two long-term supply agreements in this market...There can be no assurance that the strategic process will result in the Company pursuing any particular transaction or outcome. The SINTX Board has not set a timetable for completion of this process, and it will not disclose further developments until such time that the Company determines that further disclosure is appropriate or necessary.

09:10 EDT Rackspace Technology says FAIR has completed over 40 global AI implementations - Rackspace Technology celebrates the first anniversary of the launch of Foundry for AI by Rackspace, marking a year of groundbreaking achievements and innovation in implementing Responsible AI solutions. FAIR has completed over 40 successful global AI implementations across several industries in its first year, including financial services, real estate, education, and government services. In addition, FAIR achieved a high level of technical excellence by securing several AI, Generative AI Applications, Data, and Infrastructure certifications on Microsoft Azure, Amazon Web Services, and Google Cloud.

09:09 EDT 180 Degree Capital congratulates Matt Mclaughlin on election to Comscore board - 180 Degree Capital (TURN) congratulated Matt McLaughlin on his election to the Board of Directors of comScore (SCOR). 180 Degree Capital originally nominated Matt to SCOR's Board based on his deep background and experience in the adtech and measurement industries having served as COO of DoubleVerify Holdings. 180 Capital said, " For over two years we have sent SCOR's Board a series of private and public letters that include a myriad of recommendations we believe it could take to maximize value for all of SCOR's stakeholders. Recently, we have stayed mostly silent as we were hopeful the nomination of Matt to join SCOR's Board was an indication that it takes its governance role seriously and that it would finally take action on other pressing items. After all, representatives of SCOR's Board with whom we have spoken with, primarily its Chairman, Nana Banerjee, have repeatedly told us they aren't sitting on their hands and are contemplating many ideas for addressing these pressing issues. Alas, the only thing it appears SCOR's Board has been able to agree on is the addition of Matt to its Board; it has failed to reach conclusion on substantially all of the outstanding issues that continue to plague the value of SCOR's common stock. One would think by now there would be some level of urgency to counteract the 90% decline in the share price that has occurred under this Board's watch. Shame on us for having a glass-half-full outlook regarding the ability of this Board to create value. hat said, we will not sit idly by, and therefore we thought it would be helpful to reiterate the multitude of suggestions we have made in numerous public and private communications regarding steps that SCOR's Board and Preferred Stockholders could take to demonstrate alignment with, and create value for, all stakeholders, including common stockholders, and most importantly, the hardworking employees of SCOR: Materially lower the levels of compensation paid to SCOR's directors to be in-line with similar sized public companies. Furthermore, the Preferred representatives who are employees of the Preferred holders should waive all compensation. In 2023, SCOR's completely ineffective Board received aggregate compensation of almost $900,000 in cash and $2.3 million in total when including stock-based compensation. This level of compensation by any metric is excessive, particularly given the size of SCOR, and egregious given the failure of the Board to build value for all stakeholders. We also reiterate that board compensation paid to appointees of the preferred stockholders should reduce any accrued dividends due to such preferred stockholders. Reduce the size of the Board to be comprised of those directors who provide critical value to the future of SCOR and a maximum of one director per preferred holder. The other directors can shift to board observers if their participation in meetings is viewed as imperative. While we are delighted Matt McLaughlin has joined the Board, 11 members is entirely too large for a company of this size. Persuade the Preferred Stockholders to take their historical accrued dividends and the upcoming dividend in common stock at a significant premium to the current stock price versus cash. This step will allow SCOR to retain cash for investment into its business while showing alignment with common shareholders. If the preferred stockholders show alignment with common stockholders, we believe SCOR's common stock is likely to climb well above the price at which they are willing to take their dividend. Provide transparency on processes that SCOR's Board will use if a special dividend is called. While the size of the potential special dividend will decrease materially to less than $50 million with the next scheduled normal dividend, it is incumbent on SCOR's Board to remove ambiguities around the potential remaining amount and state clearly that such payment is highly unlikely to be made, even if called, based on its responsibilities under Delaware corporate law. We will hold the Board accountable to adhere to Delaware Law on this topic. Should SCOR's Board, even with the addition of Matt, be unable to resolve its existing dysfunction, we request that SCOR hire one or more outside parties to come in and break this Board of its inability to act. A management consulting company could provide the Board with steps it can take to improve its governance and alignment with common shareholders. An investment bank would be able to provide options for how to create the most value. If that means selling the whole company, then so be it. If that means selling an asset, then do that. All we hear from representatives of SCOR is that SCOR's Board can't agree on a direction. Deadlock is completely unacceptable at this stage, and we believe SCOR's Board either needs to conclude or arrive at a process to help it conclude. We encourage SCOR's Board to publicly announce such decisions to show it is taking this step seriously."

09:06 EDT Citi starting to see benefits of unified spread products, says CEO Fraser

09:06 EDT Edible Garden implements proprietary 'Shrink Savings' solutions - Edible Garden announced the implementation of several proprietary "shrink savings" innovations related to its basil product offering, designed to reduce product spoilage typically experienced by retailers. Jim Kras, Chief Executive Officer of Edible Garden, commented, "We are excited about implementing several new proprietary innovations, primarily focused on packaging and shipping, which are expected to significantly prolong the shelf life of our basil products, thereby reducing spoilage and driving cost savings for our retail partners. These innovations are an important competitive differentiator and build on our other unique solutions. For instance, our patented self-watering in-store display has already transformed the way plants are displayed, ensuring they remain fresh for longer and greatly minimizing waste at retail outlets. Aligned with our Zero-Waste Inspired mission, these proprietary innovations allow retailers to showcase plants at their peak, minimizing waste and providing superior products to our customers. These new innovative solutions will be introduced at the Company's annual sales meeting on Thursday, June 20, 2024."

09:05 EDT SU Group enters distribution agreement for automatic doors in Hong Kong - SU Group has expanded its security products and solutions portfolio after agreeing to become the exclusive distributor of MATZ-ERREKA's automatic doors and gates in Hong Kong. The company expects this will create a new revenue stream and growth accelerator. MATZ-ERREKA is a specialist in automatic doors and automation systems, dedicated to designing, manufacturing and installing automated systems for entrances and automatic access control. Headquartered in Spain, MATZ-ERREKA has a foothold in South America, Europe, Mexico, India and Thailand.

09:04 EDT Quad/Graphics partners with Swiftly - Quad/Graphics has partnered with Swiftly, a retail technology and media company, to distribute engaging brand content on In-Store Connect by Quad, an in-store retail media network. The collaboration supports Quad's ongoing focus to advance the in-store shopping experience by leveraging Swiftly's industry-leading platform to bring the best elements of digital commerce into physical store environments.

09:04 EDT Bion Environmental, Stovall Ranching partner to produce Montana beef - Stovall Ranching Companies and Bion Environmental Technologies will partner to develop a new-generation cattle feeding facility. Turk Stovall will join Bion's Board of Directors and lead a joint venture between Stovall Ranching Companies and Bion to develop the project. The facility will produce premium quality Montana beef that the partners believe will be the 'cleanest', most eco-friendly finished beef in the marketplace. Thee Stovall/Bion cattle project is planned to construct a 15,000 head capacity facility at Stovall's Yellowstone Cattle Feeders, in Shepherd, Montana. Cattle will be finished in barns designed for feed efficiencies and cattle welfare, while being outfitted with solar generation and advanced waste treatment and resource recovery systems provided by Bion's patented closed-loop technologies. The Bion Gen3Tech system will harvest organic and low-carbon nitrogen fertilizers from the volatile ammonia in the waste, methane that can be upgraded to Renewable Natural Gas, and clean water. Resource recovery will simultaneously minimize the facility's environmental impacts to air or water. Most of the facility's energy requirements are anticipated to be generated onsite with solar. Environmental benefits and improved resource efficiencies will be independently verified and communicated to stakeholders, and to consumers that increasingly demand eco-sustainable choices and are willing to pay for it.

09:03 EDT Seagate teams up with eBay to expand hard drive circularity program - Seagate Technology (STX) announced its sustainability collaboration with e-commerce site eBay (EBAY). The agreement establishes Seagate's official storefront on eBay as a direct channel for consumers to access factory-recertified hard drives as part of the Seagate Circularity Program.

09:02 EDT Sally Beauty, Instacart partner to offer same-day delivery - Sally Beauty, the professional hair color and care retailer under Sally Beauty Holdings (SBH), and Instacart (CART) announced a nationwide partnership to offer same-day delivery in as fast as an hour from more than 2,200 Sally Beauty store locations across the country. Customers can now select from over 7,000 products, including hair color, hair care products, and items for skin and nails from proprietary brands, delivered directly to their doorstep. Following a successful initial collaboration with Instacart earlier this year, the partnership with Sally Beauty is now available nationwide. This collaboration combines Instacart's efficient delivery network with Sally Beauty's extensive range of quality beauty products to offer consumers unparalleled convenience.

09:01 EDT Azek announces $50M accelerated share repurchase program - The AZEK Company (AZEK) announced it has entered into an accelerated share repurchase agreement with Goldman Sachs (GS) to repurchase $50 million of the Company's Class A common stock.

08:57 EDT NeoVolta expands into high-potential regions such as Hawaii, Texas, Florida - NeoVolta announced a compelling shareholder letter from newly appointed CEO Ardes Johnson. The letter outlines Johnson's strategic initiatives aimed at driving rapid growth and seizing opportunities in the residential and commercial energy storage markets. National Sales Team Formation: NeoVolta has successfully assembled a national sales team targeting key renewable energy distribution centers, ensuring a robust presence across the U.S. Strategic Partnerships Initiated: The company has begun collaborations with leading solar installers in California, Nevada, and Florida, positioning itself to capture a larger market share. Advanced Conversations for Next-Gen Systems: Johnson initiated discussions with partners to develop the next generation of NeoVolta's energy storage systems, setting the stage for future innovation. Upcoming Strategic Moves for Rapid Growth: Expansion into Top U.S. Markets: NeoVolta is actively expanding into high-potential regions such as Hawaii, Texas, Florida, and Puerto Rico, with regionally based sales teams to maximize reach and service.

08:55 EDT ECD Automotive Design begins production of custom Mustang - ECD Auto Design begins production of its first custom Mustang. As the classic Ford Mustang celebrates its 60th anniversary, ECD Auto Design is reimagining the classic car experience with never-before-seen levels of craftsmanship and modern performance upgrades. Please CLICK HERE for photos and video. For sixty years, the Ford Mustang has enchanted car enthusiasts with its power, style, and cultural allure, becoming synonymous with American performance and style. Every custom Mustang built by ECD Auto Design will be a one-of-one masterpiece paying homage to the iconic design of the past with updated features to improve performance, safety, and comfort.

08:51 EDT Camber Energy announces pilot pogram with telecom provider in Western Canada - Camber Energy announced a new project with Western Canada's largest telecom provider concerning the installation, servicing and testing of a unique Hybrid Generator system utilizing cutting edge Lithium Titanate Oxide Battery storage, commonly referred to as "LTO batteries", to support continuous connectivity to cell towers in remote regions in the country. The pilot project will take place near Conklin, AB, where the average winter temperature hovers around three degrees Fahrenheit. The sub-zero conditions in this strategically selected location will truly test the performance of the LTO batteries as they are included in a sophisticated, hybrid generator system designed to provide uninterrupted cellular connectivity at a lower cost than traditional methods. If this industry-leading initiative is deemed successful, the telecom provider proposes to convert approximately fifty additional sites to a hybrid power support system, resulting in approximately twenty-five percent less fuel consumption at these remote locations. Camber's majority-owned subsidiary, Simson-Maxwell Ltd., has been engaged to manage this special pilot project in Conklin. Separate from this engagement, Simson-Maxwell Ltd. services approximately 800 power systems on behalf of this leading telecom provider.

08:49 EDT VivoPower's Tembo secures 200 Tuskers worth $10M - VivoPower International announced that its electric vehicle subsidiary, Tembo E-LV has secured a minimum 200 committed Tembo Tuskers, its full electric pick up utility vehicle for delivery to customers and partners in Australia and New Zealand by February 2026. This is following Australian pick up truck sales in May 2024 of approximately $700m and stronger than expected interest at a leading Australian mining focused trade show. The Tembo Tuskers come in both left hand and right hand configurations, with single and dual cab options available. They have a base range of 330 kilometres, as well as a payload capacity of 1 tonne, and an unbraked towing capacity of 750 kilograms. Importantly they are priced at 15% below other comparable electric utility vehicles in the launch markets of Australia and New Zealand. The initial order of Tembo Tuskers is being prepared for delivery to partners and customers in Australia, with full on-road homologation on track to be granted by July 2024. Tembo will now seek to fast track its strategy of bringing the Tuskers to other markets where it has customers and partners, including the United Arab Emirates, Africa, Europe, Asia and Canada, amongst others.

08:48 EDT VCI Global partners with Treasure Global for e-commerce in Southeast Asia - VCI Global Limited (VCIG) through its subsidiary, Credilab unveiled its strategic collaboration with Treasure Global (TGL) to enhance TGL's e-commerce platform, ZCITY App, into an advanced AI-driven Super App. In this strategic partnership, VCIG will leverage TGL's extensive user base of approximately 3 million users, gaining immediate market access to expand its comprehensive suite of financial services. As fintech assumes a pivotal role in today's digital economy, its impact on e-commerce is indispensable, offering sophisticated tools and platforms that seamlessly streamline transactions. In this new partnership, Credilab is bringing its cutting-edge proprietary fintech and microfinancing capabilities and leveraging VCIG's collaboration with Cogia GmbH, offering industry-leading secured messaging technology, which converges fintech and e-commerce. By incorporating secured messaging, a digital wallet, and AI-driven microfinancing features into TGL's ZCITY Super App, this integration promises a revolutionary unified platform that elevates every aspect of digital transactions, delivering a seamless, secure, and highly efficient user experience.

08:46 EDT Reborn Coffee launches on Amazon, expanding OMNI-channel strategy - Reborn Coffee announced its official launch on Amazon. This strategic move enhances the Company's OMNI-channel approach, aiming to drive substantial revenue growth and capture a wider online customer base. According to Grand View Research, the global coffee market is projected to reach $144.7B by 2025, with a significant portion driven by specialty coffee. In the United States alone, the online specialty coffee market is expected to grow at a CAGR of 8% from 2023 to 2025, reaching an estimated value of $5.5B by 2025

08:43 EDT Intelligent Bio Solutions begins subject dosing, sampling for PK study - Intelligent Bio Solutions is entering the next phase of its planned 510(k) submission to the FDA. The Company has successfully completed subject screening for its Pharmacokinetic Study and will begin dosing and sampling study subjects today. INBS' PK study is a key step towards the Company's planned 510(k) submission to the FDA during the fourth quarter of this year. FDA clearance is required to show that INBS' fingerprint drug screening technology is safe and effective and would result in the Company's ability to enter the substantial US market, currently planned for the first half of 2025. INBS aims to complete the dosing and sampling of the recruited subjects by the end of June 2024, with a review of the PK study results expected to be finalized by the end of July 2024. The PK study will provide insights into the metabolism, distribution, and excretion of opiates, with a specific focus on human sweat. The study will gather and analyze fingerprint sweat samples and compare the results with blood, saliva, and urine samples.

08:41 EDT Banzai releases mid-year customer satisfaction results - Banzai International announces its record-setting mid-year customer satisfaction results for 2024. Demonstrating unwavering commitment to excellence, for the year to date 2024, Banzai has achieved an outstanding Net Promoter Score of 53 and an exceptional Customer Satisfaction score of 96.1%. These remarkable metrics underscore Banzai's dedication to exceeding customer expectations consistently. An NPS of 53 places Banzai in the 'excellent' category, reflecting the high likelihood of customers to recommend Banzai's solutions to others. The CSAT score of 96.1% signifies top-tier performance, indicating that Banzai's customers are overwhelmingly satisfied with their experiences. In addition to these achievements, Banzai is honored to have received the prestigious CMSWire IMPACT Gold award in the Customer Journey Innovation category. This accolade recognizes outstanding contributions to enhancing customer experiences and digital marketing. Banzai's innovative approach has significantly optimized customer journeys and increased net revenue retention.

08:40 EDT Kopin receives contract from U.S. Army to develop AR display optics - Kopin Corporation announced it has received a contract from the U.S. Army to develop novel see-through Augmented Reality, AR, display optics for dismounted soldier vision system applications.

08:40 EDT Iteris selected to support IIJA-funded northwestern Illinois region - Iteris announced it has been chosen to support Stephenson County, Illinois and the Blackhawk Hills Regional Council in completing a safety analysis of the area's transportation infrastructure. Iteris is subconsultant to Kaskaskia Engineering Group, a trusted local full-service civil engineering, environmental, and contracting firm. Iteris will be an active part of their team, providing a safety analysis, equity analysis, and an identification of safety improvement countermeasures for the rural six-county area in Northwestern Illinois. The aim of the project is to comprehensively evaluate safety challenges in the area to identify solutions that can help the region's crash reduction goals. This project is funded by the Safe Streets and Roads for All initiative, an important federal safety grant program under the Infrastructure Investment and Jobs Act, IIJA.

08:38 EDT OSI Systems receives $7M order for optical sensors - OSI Systems announced that its Optoelectronics and Manufacturing division has received an order totaling approximately $7 million to provide navigation sensors to a leading aerospace and defense OEM. OSI Systems' Chairman and Chief Executive Officer, Deepak Chopra, commented, "This order highlights our sensors' critical role in leading aerospace and defense applications. We are pleased to support our customer's advanced navigation systems with our reliable, high-performance technology."

08:37 EDT Sidus Space announces successful demonstration of advanced solution - Sidus Space has announced the successful demonstration of an advanced software solution supported by its FeatherEdge technology aboard its LizzieSat satellite, which launched in March 2024 on SpaceX's Transporter-10 mission. This innovation, achieved in collaboration with Xiomas Technologies, represents a significant milestone in the NASA-funded initiative to develop advanced thermal sensors, setting a new standard in space-based thermal sensing systems.

08:37 EDT Chijet Motor initiates business of automobile culture tourim - Chijet Motor Company announced that on June 7, The holding subsidiary FAW Jilin Automobile of Chijet Motor signed an intention agreement with the administration committee of Jilin National High-tech Industrial Development Zone and Haikou BIAOCHI Automobile Culture Development for automobile industry culture tourism and race automobile R&D and manufacture. FAW JiLin and BIAOCHI will cooperate to do project of automobile culture tourism with northeast ice-snow tourism characteristics. Depending on the automobile R&D and manufacture system of FAW JiLin, a kart, ATV & UTV new energy and fuel automobile manufacture base will be constructed in the factory of FAW JiLin in the future. In addition, a comprehensive cultural tourism base with kart track, off-road track, rallying field and RV camping will be constructed nearby. The industrial cultural tourism project integrates automobile race, automobile development, RV camping, music and gastronomy.

08:36 EDT Day One Biopharmaceuticals in pact with MabCare for MTX-13 targeting PTK7 - DayOne Biopharmaceuticals announced it has entered into an exclusive licensing agreement with MabCare Therapeutics MabCare for MTX-13, a novel ADC targeting protein-tyrosine kinase 7 PTK7 . Pursuant to the terms of the Agreement, Day One has exclusive rights to develop, manufacture, and commercialize MTX-13 worldwide, excluding Greater China. In April 2024, the U.S. Food and Drug Administration cleared the investigational new drug application for MTX-13, which going forward will be identified as DAY301. In pre-clinical studies, DAY301 showed antitumor activity in a wide range of solid tumors "Our priorities for 2024 are to successfully launch OJEMDA tovorafenib , to advance our existing programs and to expand our pipeline by in-licensing clinical-stage assets that have the potential to transform outcomes for patients of all ages living with cancers," said Jeremy Bender, Ph.D., chief executive officer of Day One. "We are excited by the opportunity presented by DAY301, and we believe we have the right team in place to develop the program to its full potential."Under the terms of the licensing agreement, MabCare will receive $55M upfront, and is eligible to receive an additional $1.152B in development, regulatory and commercial success-based milestones, plus low-to-mid single-digit royalties on net sales outside of Greater China. Day One expects the first patient to be dosed in the Phase I study in the fourth quarter of 2024 or first quarter of 2025

08:35 EDT Verint announces leading U.S. travel company using Verint bots - Verint announced that a leading U.S. travel company has been using Verint bots to achieve successful self-service containment of 95 percent of their customer interactions. The travel company is using Verint's AI-powered IVA to handle six million digital customer interactions per year related to travel booking, changes and cancellations. The company also reported positive customer experiences when their customers interacted with the Verint bots.

08:33 EDT Cenntro Electric announces deliver of more than twenty Logistar 400 vehicles - Cenntro announced it has delivered more than twenty US Assembled Class 4 Logistar 400 vehicles to its customers and dealers in the month of May, 2024. "After thorough testing and certification, we are ramping assembly and delivery of the LS400 to our west coast and broader US customer base," said Peter Wang, Chief Executive Officer of Cenntro. "We are seeing strong interest in the LS400 and future series models which are currently undergoing testing and certification."

08:32 EDT La Rosa Holdings plans acquisition of controlling interest in Red Door Title - La Rosa Holdings announced that it has entered into a non-binding Letter of Intent to acquire a controlling interest in Nona Title Agency, which operates under the name Red Door Title, a full-service escrow settlement and title company headquartered in Orlando, Florida. The Company anticipates finalizing the transaction by the end of July. Once complete, the transaction would allow La Rosa to provide title insurance services for home purchases and sales, complementing its existing real estate offerings. Securing title insurance capabilities would position the Company to deliver more comprehensive solutions within the residential property market... The consummation of the acquisition is subject to the parties entering into a definitive acquisition agreement and other related transactional documents.

08:24 EDT Aytu BioPharma announces paydown, refinancing of term loan - Aytu BioPharma announced the refinancing of its existing term loan and extension of its revolving credit facility on more favorable terms to the Company. In addition, the Company received $3.5 million of additional capital through the exercise of warrants from its June 2023 equity financing, a portion of which was used to pay down the term loan indebtedness. On June 12, 2024, the Company entered into a new $13.0 million secured, amortizing term loan with Eclipse Business Capital at an interest rate of the secured overnight financing rate as administered by the SOFR Administrator plus 7.0%. The Eclipse Term Loan replaces the Company's previous $15.0 million secured term loan with Avenue Capital Group II, which would have had an effective interest rate today of 15.9%. The Eclipse Term Loan will mature on June 12, 2028, with a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four-year term of approximately $5.6 million to be repaid at maturity. The approximate 350-basis point reduction in the interest rate results in a potential savings of $1.3 million in interest expense under the new Eclipse Term Loan compared to the interest rate under the Avenue term loan. Further, the refinancing improves the Company's balance sheet by reclassifying a significant majority of the term loan indebtedness from current liabilities to long-term liabilities and decreasing the overall indebtedness from $15.0 million to $13.0 million, helping to improve key financial ratios. On June 14, 2024, warrants to purchase 2,173,912 common shares at $1.59 per share issued with the Company's June 2023 equity financing were exercised, generating proceeds of $3.5 million. The warrants were converted into 367,478 shares of common stock and 1,806,434 pre-funded warrants to purchase shares of common stock with an exercise price of $0.0001 per share. The Company used a portion of these proceeds to pay down $2.0 million in term loan indebtedness along with closing costs. As of June 18, 2024, the Company had 5,972,327 shares of common stock outstanding. On June 12, 2024, the Company also extended the maturity date of its existing revolving credit agreement with Eclipse to June 12, 2028. The amendment of the revolving credit facility also provides for an increase in potential maximum borrowing capacity to $14.5 million and other terms deemed to be more advantageous to the Company.

08:22 EDT Autonomix announces data on 1st five lead-in patients in human clinical trial - Autonomix Medical announced preliminary positive results from the first five "lead-in" patients in the Company's ongoing proof-of-concept PoC human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. The goal of this trial is to assess pain reduction via radiofrequency RF ablation. The Company's catheter-based microchip sensing array used to detect and differentiate neural signaling was not used in this trial and will be evaluated in future studies. "We are very pleased with these initial positive results, which confirm our ability to treat this historically difficult-to-treat cancer pain with catheter-based transvascular RF ablation. While preliminary, we are highly encouraged with the level of pain reduction and quality-of-life improvement these patients gained and we hope continue throughout the remainder of the trial. While these data will not be included in the final analysis, they provided our clinical team valuable insight into optimizing the procedure, particularly the catheter entry point, where 3 of the 5 patients who saw a pain response had femoral access of the catheter and the 2 that did not respond had brachial access. We believe access factors played a role in the ability to ablate the appropriate nerves to see mindful pain reduction in the brachial access patients, as the bias of the catheter appears less optimal in ablating the target nerves from this approach to the target anatomy," commented Dr. Robert Schwartz, Co-Founder and Chief Medical Officer of Autonomix.

08:20 EDT Reunion Gold provides reminder regarding expiry of warrants - Reunion Gold wishes to remind holders of outstanding common share purchase warrants issued on July 8, 2022 that the Warrants will expire at 4:00 p.m. Vancouver time on Monday, July 8, 2024. As of June 14, 2024, there were 41,338,257 Warrants outstanding. Each whole Warrant entitles its holder to purchase one common share of Reunion Gold at an exercise price of C$0.39 per share. Any Warrants not exercised prior to 4:00 p.m. Vancouver time on July 8, 2024 will expire and become void, and the holder will no longer be able to exercise such voided Warrants.

08:19 EDT Workiva announces launch of Workiva Carbon - Workiva announced the launch of Workiva Carbon. The new offering advances its ESG and Sustainability Platform for organizations to support the requirements of global climate regulations, including the Corporate Sustainability Reporting Directive, CSRD, SEC's climate disclosure rules, and California's Climate Corporate Data Accountability Act and Climate-Related Financial Risk Act. Workiva Carbon simplifies the management of net zero targets that thousands of organizations have established voluntarily to meet international guidelines, respond to stakeholder demands for transparency, and better compete in the global economy.

08:18 EDT LL Flooring mails letter to shareholders on upcoming 2024 Annual Meeting - LL Flooring mailed a letter to shareholders in connection with the Company's upcoming 2024 Annual Meeting of Stockholders. The letter contains critical information for shareholders' decision making, including highlighting how the LL Flooring Board and management team have taken and continue to take action to implement change while Thomas Sullivan and his two other director nominees risk the Company taking a significant step backwards. The Board continues to believe that replacing three of the LL Flooring Board's nominees is not only unnecessary, but would remove superior talent, critical skills and three independent directors from the Board and risk derailing progress being made at the Company.

08:18 EDT Digimarc, OMRON partner to modernize industrial automation - Digimarc Corporation and OMRON announced a strategic partnership to take industrial automation solutions to a new level. The combination of Digimarc digital watermarks with OMRON machine vision technology represents an innovative approach to digital product identification and a transformative new force in industrial automation. Together, the companies are helping manufacturers and brands stay ahead of the competition, adapt to changing market conditions, and meet the increasingly stringent requirements of sustainable, customized products.

08:16 EDT AgriFORCE Growing Systems appoints Jolie Kahn as CEO - AgriFORCE Growing Systems (AGRI) announces the appointment of Jolie Kahn as new CEO for the Company. Kahn was most recently with Marathon Digital Holdings (MARA) where she served as General Counsel from 2019 to 2023.

08:15 EDT Arq secures second contract for granular activated carbon facility - Arq announced its second major sales contract for the supply of GAC to be produced from its strategic Red River facility. This agreement, with a company specializing in the manufacturing of personal and industrial air purification devices, has a commencement date of January 2025 and scales up to an ultimate run-rate requirement of 4 million pounds of GAC per year. This second GAC contract is in addition to the 5 million pound per year agreement announced in May 2024. At its 4 million pound per annum run-rate and in conjunction with the previously announced contract, these two agreements reflect approximately 36% of the Red River facility's initial 25 million pounds per year GAC nameplate capacity, due to come online by year-end 2024.

08:14 EDT authID and Syntrove announce OEM partnership, terms undisclosed - authID announced they have signed an OEM agreement that will integrate authID's biometric capabilities in fighting malicious, generative AI-driven fraud, deepfakes, and cyberattacks into the Syntrove offering. Syntrove, whose vision is to be at the forefront of technological and process evolution, will now distribute authID's next-gen authentication solutions to its portfolio of leading banking, insurance, gaming, crypto and supply-chain enterprise customers to stop fraud with the strongest identity assurance available in the market. "Our partnership with Syntrove is a force multiplier that helps accelerate the delivery of our next-gen biometric authentication solutions into a broad set of verticals. We are excited to work with Syntrove to onboard our first joint customer from the gaming industry to secure workforce identity," said Rhon Daguro, CEO of authID. "Combining Syntrove's stellar risk-management expertise and technology platform with authID's trusted identity assurance, precision, and seamless user experience delivers a leading market differentiator to help stop fraud, detect deepfakes, and combat generative adversarial AI fraud." Digital enterprises today confront ever-increasing risk from fraudsters who leverage AI to generate fake ID's and deepfakes that compromise digital account openings, foil current risk reviews, and accelerate account takeovers and asset seizures. Needing a trusted technology partner to defeat these challenges, Syntrove recognized the value of authID's next-gen biometric identity life-cycle platform, ease of integration, and lightning-fast experience.

08:13 EDT Lexicon announces publication on cost-effectiveness of INPEFA - Lexicon Pharmaceuticals,announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. The analysis was conducted from a U.S. healthcare sector perspective, in accordance with Consolidated Health Economic Evaluation Reporting Standards. Results from this study showed that lifetime quality-adjusted life-years were 4.43 and 4.04 in the INPEFA and placebo groups, respectively. In another study, "Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure," recently published in the Journal of Comparative Effectiveness Research, the research team used published real-world data to derive baseline event frequencies and SOLOIST-WHF study data to estimate the efficacy of INPEFA. According to the research results, the use of INPEFA led to a net gain in QALYs of 0.425 for INPEFA versus standard of care. The investigators concluded that INPEFA is a cost-effective addition to standard of care for patients hospitalized with heart failure and comorbid diabetes.

08:12 EDT ChargePoint, LG join forces to innovate EV charging - ChargePoint and LG Electronics have formed a strategic partnership to leverage their respective strengths for future innovations in EV charging. The first output of this relationship will be commercial charging solutions that encompass ChargePoint's industry-leading charger management software and LG's advanced EV charging hardware, with deliveries expected to begin later this summer. Future areas of collaboration may include combining ChargePoint EV charging solutions with LG energy storage systems, integration of the LG ThinQ smart home platform with ChargePoint's award-winning Home Flex residential charger, and chargers that leverage LG's digital-out-of-home advertising platform, among other areas under evaluation.

08:11 EDT Aquestive Therapeutics to join Russell 3000, Russell 2000 Indexes - Aquestive announced its expected addition to the broad-market Russell 3000 and Russell 2000 Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024.

08:09 EDT TransAct Technologies announces new BOHA! international market win - TransAct Technologies announced that it has landed a significant sale in the Italian market of its existing international QSR customer for one BOHA! Terminal 2 each to 200 locations. This win marks the fifth international market where TransAct has gained approval and subsequently sold the new BOHA! Terminal 2, with the other four markets being Canada, Germany, Poland, and Saudi Arabia. Italy alone represents the opportunity for up to 500 additional BOHA! Terminal 2 sales.

08:08 EDT COMSovereign adds Intelligent Waves as solutions partner - COMSovereign Holding has added Intelligent Waves as a new solutions partner for its full array of hardware and software solutions and products as it seeks to expand its sales into the large Government and Department of Defense markets. Under the terms of the agreement, IW will serve as an authorized solutions partner of COMSovereign's full array of secure 5G wireless connectivity and aerostat/drone platforms. IW will also support the sales of the Software-as-a-Service, cloud-based network change monitoring and compliance software from the Company's partner, SIFF.IO. As a specialized provider of communications, security and networking technologies supporting the U.S. DoD, IW will serve as the Company's integration and management services provider supporting sales to the U.S. Government.

08:06 EDT Hawaiian Holdings, Plusgrade announce multi-year partnership - Plusgrade announced a multi-year partnership with Hawaiian Airlines, Hawaii's biggest and longest-serving airline. Plusgrade's loyalty business unit, Points, will now power the Buy and Gift loyalty solutions for HawaiianMiles, giving members the ability to easily buy and gift miles. This enhancement provides HawaiianMiles members the convenience of purchasing miles online, expediting their ability to redeem miles for their next Hawaiian Airlines flight. Through this expanded collaboration, Hawaiian Airlines leverages Plusgrade's technology and analytics to bolster member loyalty and ancillary revenue. Plusgrade will power the "Buy Miles'' feature, allowing members to make lump-sum purchases of miles, and "Gift Miles," enabling members to buy HawaiianMiles for their family and friends.

08:04 EDT Starbucks, Marriott Bonvoy announce new collaboration - Marriott Bonvoy, Marriott International's (MAR) award-winning travel program and marketplace, and Starbucks (SBUX) announced a new collaboration offering distinctive benefits to loyalty members. Marriott Bonvoy members and Starbucks Rewards U.S. members who link loyalty accounts will have the opportunity to earn more Stars toward free beverages, food and more at Starbucks1, and Marriott Bonvoy points that can be redeemed at Marriott Bonvoy's more than 30 brands and 10,000 global destinations as well as for Marriott Bonvoy Moments experiences.

08:02 EDT First Onsite announces new branch in Roanoke, Virginia - First Onsite Property Restoration has expanded operations and opened a new branch in Roanoke, Virginia to serve the city and the surrounding area. This is the company's second new branch in Virginia following last week's announcement of its new branch in Richmond. The Roanoke branch offers businesses First Onsite's core commercial restoration services such as water, fire, storm, and mold mitigation and remediation, with a focus on the healthcare industry. The addition of this branch was born from the identified need to expand the healthcare offerings in both the Roanoke and Lynchburg geographical areas in the Mid-Atlantic region. Gary Strickland will lead the new branch as its General Manager.

08:01 EDT Merck, MJFF offer service to advance Parkinson's research - Merck and The Michael J. Fox Foundation for Parkinson's Research, MJFF, are advancing research aimed at slowing progression of Parkinson's disease, PD. Through funding from MJFF's "Biomarkers to Support Therapeutic Trials Program", Merck's SMCxPRO immunoassay technology has been used to help detect low levels of a biomarker associated with cell dysfunction in patients. Now, the service is available to the scientific community through support from the MJFF. This will make it possible to track the response of different therapeutic options to disease progression.

07:56 EDT Dentalcorp promotes Tchaplia as CFO, Mosher as Executive Director - dentalcorp Holdings announces that it has bolstered its senior leadership team by promoting Nate Tchaplia, the Company's Chief Financial Officer, CFO, to the role of President, effective immediately. In addition, Kevin Mosher, a member of the Company's Board of Directors, will immediately assume additional responsibilities as Executive Director.

07:52 EDT Rocket Lab signs deal for 10 electron launches with Synspective - Rocket Lab USA last night announced it has signed the largest Electron launch agreement in the company's history; a ten-launch deal with Japanese Earth observation company Synspective. The agreement was announced in Tokyo at an event attended by Rocket Lab founder and CEO Sir Peter Beck, Synspective founder and CEO Dr. Motoyuki Arai and New Zealand Prime Minister, the Right Honorable Christopher Luxon, who is in Japan with a business delegation to deepen ties and accelerate growth in technology and other sectors. Rocket Lab has been the sole launch provider for Synspective since 2020, successfully launching four missions for the Japanese Earth observation company to date.

07:48 EDT Hershey updated 2030 greenhouse emissions reduction targets - Hershey has updated its 2030 science-based greenhouse gas emissions reduction targets against the latest standards. Hershey's target to reduce scope 1 and 2 GHG emissions by 50% by 2030 from a 2018 baseline was re-validated by the Science Based Targets initiative - SBTi -. To date, Hershey has achieved a 43% reduction against this target. The company has also set near-term Forest Land and Agriculture and non-FLAG targets. It is committed to reduce scope 3 Forest Land and Agriculture emissions by 36% and non-FLAG emissions by 30% by 2030. Hershey implements a variety of programs and initiatives across its operations and its supply chain to reduce its carbon footprint. To improve energy consumption and efficiency, Hershey has created a cross-functional team to oversee delivery of plant-level energy reduction targets.

07:46 EDT Swiss regulator finds HSBC violated money laundering rules - HSBC Private Bank SA breached its obligations in the prevention of money laundering in connection with two politically exposed persons and thereby seriously violated financial market law. This was established in the context of enforcement proceedings by the Swiss Financial Market Supervisory Authority FINMA, which has imposed measures to ensure that compliance with the law is restored. The decision orders that, until these measures have been implemented in full, the bank may not enter into any new business relationships with politically exposed persons. FINMA has ordered the bank to conduct a review, with regard to anti-money laundering aspects, of all the current high-risk business relationships and business relationships with politically exposed persons. It must also check the correct categorization of the risks presented by its other customers. An audit agent will monitor the implementation of these measures on site on an ongoing basis and will submit a report to FINMA. The bank may not enter into any new business relationships with politically exposed persons until such time as completion of the reviews has been confirmed by the audit agent. In addition, HSBC Private Bank [Suisse] SA must issue FINMA with a comprehensive presentation of the responsibilities within its board of directors and executive management as well as details of how they are assigned. The decision has not entered into force. Reference Link

07:43 EDT Arch Biopartners gets University of Calgary CHREB approval for Phase II trial - Arch Biopartners announced that the University of Calgary's Conjoint Health Research Ethics Board has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury. The clinical team at the University of Calgary Cumming School of Medicine is now able to work with Arch to complete preparation and training to enable the start of patient recruitment in Calgary. This work will be completed while waiting for the expected final approval from Alberta Health Services. The trial continues to have patient recruitment at five clinical sites in Turkey. Since the trial began dosing patients in March, there have been enhancements to the design of the study protocol to help improve the execution of the trial. These changes have since been approved by Health Canada and are pending approval by the Turkish Ministry of Health.

07:40 EDT Clubhouse Media announces Maya Spielman joins HoneyDrip.com - Clubhouse Media announced that Playboy model and comedian, Maya Spielman, has joined HoneyDrip.com. Spielman has performed stand up comedy in numerous venues, including Flappers Comedy Club and The Comedy Chateau. She has a large following, boasting 215k+ followers on Instagram alone. Honeydrip.com is a digital platform designed and wholly owned by CMGR with a focus on the empowerment of creators. The site allows creators to connect and engage with fans and monetize exclusive content.

07:37 EDT Intra-Cellular announces results for lumateperone as adjunctive therapy in MDD - Intra-Cellular Therapies announced positive topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD. This trial, in conjunction with our previously reported positive Phase 3 study, Study 501, forms the basis for our lumateperone sNDA for the adjunctive treatment of MDD. We expect to submit this sNDA to the U.S. Food and Drug Administration FDA n the second half of 2024."We are confident that the efficacy results from Studies 501 and 502, along with the favorable safety and tolerability profiles from these studies, will make lumateperone a drug of choice for patients suffering with MDD who are having an inadequate response to antidepressant therapy," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. ...These results, further support our vision for CAPLYTA to become a leading option for patients and providers across mood disorders."...Supplemental NDA sNDA submission for the adjunctive treatment of major depressive disorder MDD anticipated in the second half of 2024...

07:33 EDT Namib Minerals, Hennessy Capital Investment VI enter business combination deal - Namib Minerals and Hennessy Capital Investment Corp. VI have entered into a definitive business combination agreement The proposed business combination is expected to be completed in the fourth quarter of 2024, subject to customary closing conditions, including regulatory and stockholder approvals. The combined public company is expected to be named "Namib Minerals" and to list its common stock and warrants to purchase common stock on Nasdaq under the new ticker symbols "NAMM" and "NAMMW", respectively, subject to approval of its listing application. The Proposed Business Combination consideration of approximately 50 million PubCo ordinary shares values Namib at a pre-money enterprise value of $500 million, with up to an additional 30 million PubCo ordinary shares tied to the completion of operational milestones, including the commercial production of the Mazowe and Redwing mines. The Proposed Business Combination is expected to deliver net proceeds to Namib of approximately $91 million, assuming no further redemptions by HCVI's public stockholders, as well as approximately $60 million of additional funding from one or more financing agreements with investors expected to be executed prior to the Closing. As a result of the Proposed Business Combination, Namib expects to benefit from continued operational efficiency and cash flow generation from its producing How mine and the build-out of Namib's multi-asset growth path. The Proposed Business Combination also represents the largest African deSPAC to date. Namib's existing management team, led by Chief Executive Officer, Ibrahima Tall, will continue to lead the business after the Closing. Namib's current producing asset, the How mine, is an established, high-grade, underground gold mine located near Bulawayo, Zimbabwe. The How mine is currently generating cash flow alongside a strong history of production and one of the lowest reported production cost profiles amongst its peer group. The How mine has a strong track record of consistently operating within budget and maintains additional identified underground resources, which may contribute to extending its mine life. Namib also has an identified pathway to operate as a multi-asset producer in Africa, with growth plans underway to restart the Company's previously producing Mazowe and Redwing gold mines, along with development potential in the Democratic Republic of the Congo to unlock battery metals in the region. To date, work has commenced across 13 granted exploration permits in the DRC and six initial holes have been drilled identifying copper and cobalt potential. The Proposed Business Combination implies a pro forma combined enterprise value of PubCo $609 million, excluding additional earnout consideration, on a cash-free and debt-free basis, assuming no further redemptions of HCVI's public shares and $60 million in targeted PIPE funding to be obtained prior to the Closing. The boards of directors of both HCVI and Namib have approved the proposed transaction, which is expected to be completed in the fourth quarter of 2024, subject to, among other things, the approvals by stockholders of HCVI and Namib and satisfaction or waiver of the other conditions set forth in the Business Combination Agreement. Net proceeds from the transaction are expected to enable Namib to invest further into its established How mine, while also contributing to the restart of production at two historically producing gold mines, Mazowe and Redwing, in Zimbabwe and expansion of operations into the DRC. Under the terms of the Business Combination Agreement, Namib's existing shareholders will convert 100% of their equity ownership stakes into the combined company and are expected to own approximately 71% of the post-combination company upon consummation of the Proposed Business Combination. The Proposed Business Combination has been unanimously approved by the board of directors of both Namib and HCVI.

07:28 EDT Silver Tiger Metals provides update on PFS drilling program at El Tigre - Silver Tiger Metals provided an update on the first 110 drill holes of the Company's Pre-Feasibility Study drilling program on its El Tigre Project in Sonora, Mexico. These new results are highlighting the expansion of the mineralization along the Footwall of the PEA "Starter Pit". Drill hole ET-24-583 cut from surface 79.50 metres grading 1.13 g/t gold equivalent or 84.8 g/t silver equivalent from 0.0 to 79.50 metres, consisting of 0.97 g/t gold and 12.3 g/t silver AND 26.0 metres grading 0.72 g/t gold equivalent or 53.7 g/t silver equivalent from 101.0 to 127.0 metres, consisting of 0.67 g/t gold and 3.6 g/t silver in the Hanging Wall and Footwall Zones. The hole passed through the El Tigre vein and has expanded the Footwall Zone footprint some 50m to east. New intersections through the Stockwork gold deposit, comprised of the Footwall, Hanging Wall and high-grade Keel Zones, are highlighted below, shown on Figure 2 and listed in Table 1. Drill hole ET-24-571: 44.2 metres grading 1.00 g/t gold equivalent or 75.1 g/t silver equivalent from surface to 44.2 metres, consisting of 0.49 g/t gold and 38.4 g/t silver AND 57.0 metres grading 0.32 g/t gold equivalent or 24.0 g/t silver equivalent from 55.5 to 112.5 metres consisting of 0.31 g/t gold and 1.1 g/t silver. The former Hanging Wall intersection shows consistent, higher grades at surface in the Stater Pit area and the latter Footwall intersection expand the mineralization profile 60m to east over the 2023 MRE. Drill hole ET-24-576: 41.1 metres grading 1.03 g/t gold equivalent or 77.5 g/t silver equivalent from 129.0 to 170.1 metres, consisting of 0.92 g/t gold and 8.5 g/t silver INCLUDING 14.2 metres grading 1.62 g/t gold equivalent or 121.8 g/t silver equivalent from 140.9 to 155.1 metres consisting of 1.52 g/t gold and 7.5 g/t silver gold in the Hanging Wall Zone. Drill hole ET-24-580: 27.1 metres grading 0.74 g/t gold equivalent or 55.5 g/t silver equivalent from 25.9 to 53.0 metres, consisting of 0.68 g/t gold and 4.6 g/t silver in the Hanging Wall Zone AND 9.0 metres grading 1.75 g/t gold equivalent or 131.4 g/t silver equivalent from 84.0 to 93.0 metres consisting of 1.60 g/t gold and 11.5 g/t silver in the Keel Zone showing high-grade, consistent mineralization 100m to south of PEA 'Starter Pit. Silver Tiger's CEO, Glenn Jessome, stated, "In line with previous assay results, the Footwall and Keel Zone are showing significant potential for expansion over the 2023 MRE" Mr. Jessome further stated, "The results may increase the updated MRE associated with the PFS-level study, as well as further de-risk the project."

07:25 EDT Clene presents extended survival data on CNM-Au8 from HEALEY ALS trial - Clene and its wholly owned subsidiary Clene Nanomedicine presented new long-term CNM-Au8 treatment results for survival and neurofilament light levels from the HEALEY ALS Platform Trial open label extension at the European Network for the Cure of ALS meeting in Stockholm, Sweden. The data presentation, titled "Long-Term CNM-Au8 Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial," highlights up to 42 months of survival follow-up and 76 weeks of long-term NfL biomarker results, including a responder subset from the HEALEY ALS Platform Trial in participants with ALS. All participants treated with CNM-Au8 30 mg, including ex-placebo participants who transitioned to CNM-Au8 in the OLE, with complete baseline co-variates were included in the survival analysis. Improved Survival Compared to Matched PRO-ACT Controls: Survival analyses of participants originally randomized to CNM-Au8 30 mg treatment and ex-placebo to CNM-Au8 compared to matched PRO-ACT controls up to 3.5 years post-baseline. Approximately 60% decreased risk of death in CNM-Au8 30 mg treated patients compared to matched PRO-ACT controls up to 3.5 years of follow-up; covariate-adjusted hazard ratio: 0.431, p-value = 0.0002. Reduced Neurofilament Light Biomarker Levels in NfL Responders: NfL Responder Subset: The NfL responder analysis was completed to identify NfL decreases in participants who showed consistent NfL declines. Responders were defined as participants who had all post-baseline measures with an NfL decrease or repeated declines of at least 10 pg/mL following the start of CNM-Au8 treatment: Responders demonstrated an average NfL reduction of 28%, which is suggestive of decreased axonal loss on an ongoing basis; GMR at Week 76 change vs. baseline: 0.72, pless than0.0001; The NfL results are based on earlier announced analyses of plasma NfL collected from participants in the HEALEY OLE who were treated with CNM-Au8 30 mg through week 76 compared to participants treated with placebo for 24 weeks prior to crossing over to active treatment for up to 52 weeks. Long-term treatment with CNM-Au8 30 mg resulted in continued significant decline of plasma NfL levels. The geometric mean ratio vs. placebo at week 76 was 0.841, 95% CI: 0.73 - 0.98, p=0.023. CNM-Au8 was safe and well-tolerated during the OLE.

07:17 EDT PolyPid hosts KOL call, provides update on ongoing SHIELD II Phase 3 trial - PolyPid hosted a virtual Key Opinion Leader event discussing the significant unmet medical need in the prevention of surgical site infections. The Company also provided an update on its ongoing SHIELD II Phase 3 trial for D-PLEX100. Charles E. Edmiston, Ph.D., discussed several key topics surrounding SSIs. Key takeaways include: The return to higher pre-COVID SSI rates due to the increase in the number of elective surgeries conducted and the surgical environment normalizing to levels found prior to 2020. SSIs are under-reported, and up to 30-35% of colorectal infections are missed due to sub-optimal surveillance strategies. Procedural and patient-related risk factors such as smoking, alcohol abuse, type 2 diabetes and a high BMI have a significant negative impact on the risk of developing a SSI, and this increase in risk is compounded when patients have multiple risk factors. Long term cost to commercial payers of a single colorectal SSI event over a period of 24 months can range from $44,000 to $64,000, with the cost for Medicare ranging from $20,000 to $45,000, respectively. Surgical care bundles in patients undergoing colorectal surgery significantly reduce the risk of SSIs. The 30-day high concentration release of antibiotics achieved with D-PLEX100 has the potential to add additional benefit to infection prevention bundles. PolyPid also provided an update on the enrollment of its ongoing Phase 3 SHIELD II trial of its lead product candidate, D-PLEX100. The SHIELD II clinical study includes patients undergoing abdominal colorectal surgery with large incisions and has now enrolled approximately 250 patients of a planned total of approximately 600 subjects. Approximately 50 centers are currently open and recruiting patients. Top-line results are expected in the first quarter of 2025. The Company intends to conduct an unblinded interim analysis once a total of approximately 400 patients complete their 30-day follow-up, which is anticipated to occur in the fourth quarter of 2024.

07:17 EDT KKR releases 2024 mid-year global macro outlook - KKR released its 2024 mid-year global macro outlook by Henry McVey, CIO of KKR's Balance Sheet and Head of Global Macro and Asset Allocation. McVey and his team explain why they believe the current economic cycle has further to run, despite an environment of heightened volatility and political complexity that they envision in the second half of 2024. Several factors underpin the team's constructive outlook, including an encouraging technical backdrop, a belief that the company has entered a structurally higher level of productivity in the U.S., a stronger global employment market versus prior cycles, central bank balance sheets that are still plump relative to history, and a surprisingly strong global capex cycle. They also highlight several notable updates since their 2024 Outlook: Stronger conviction in the importance of owning more non-correlated assets, given a flatter frontier for expected returns amidst heightened portfolio volatility. More pronounced mismatch between energy supply and demand given electrification needs and the growth of energy-intensive users such as data centers, semi fabs, EV battery plants and steel mills. Broadening of earnings growth across sectors and geographies, which we expect will bring more balance to the equity markets. More sustained deficits amidst election volatility, which reinforce our Regime Change thesis and continued belief that the deficit will stabilize at historically wide levels under either U.S. presidential administration. Greater focus on the positive path for productivity.

07:14 EDT Dorman Products releases hundreds of aftermarket-exclusive repair solutions - Dorman Products announced the release of hundreds of new aftermarket automotive components and assemblies. The new products add to an expansive catalog of more than 120,000 SKUs, a depth and diversity of coverage offering millions of new sales and repair opportunities for customers throughout North America.

07:14 EDT N-able issues pledge on responsible use of AI - N-able announced its Pledge on the Responsible Use of Artificial Intelligence. The pledge describes the company's commitment to openness and protecting partner data and intellectual property. The newly unveiled AI strategy outlined in the pledge is built on three pillars: consent, transparency, and context-and designed to foster user control and privacy, clear communication, and appropriate use.

07:13 EDT 908 Devices announce enhanced qualification package for XplorIR - 908 Devices announced an enhanced quantification package for its XplorIR handheld gas and vapor analyzer. With this software update, the device, part of 908 Devices' acquisition of RedWave Technology, can now quantify nearly 5,000 airborne chemicals. XplorIR empowers fire departments, HAZMAT teams and other first responders with mission-critical information and enables decisions around personal protective equipment, ensures swift remediation efforts and reduces dangers to first responders and the public.

07:12 EDT PureTech Health appoints Loebel as CMO, Gladstein as General Counsel - PureTech Health announced it has expanded its executive team with the appointment of Antony Loebel, M.D., as Chief Medical Officer, CMO, and President of Clinical Development, and Lana Gladstein, J.D., as General Counsel. Dr. Loebel was most recently the President and Chief Executive Officer of Sunovion Pharmaceuticals. Most recently, Gladstein was the Group General Counsel at APRINOIA Therapeutics, a clinical-stage company developing therapeutics and diagnostics for neurodegenerative diseases.

07:10 EDT MAG Silver reports annnual general, special meeting results - MAG Silver reports that at its Annual General and Special Meeting held on June 17, 2024, MAG's shareholders approved by majority: to elect all eight directors standing for election, to re-appoint Deloitte LLP as auditors of the Company, and to support the Company's approach to executive compensation.

07:09 EDT Chemomab: Publications 'reinforce' potential of I CCL24 antibody for PSC - Chemomab Therapeutic announced a new scientific publication that further confirms the important role of the soluble protein CCL24 in the pathologies underlying the rare fibrotic liver disease primary sclerosing cholangitis PSC. The new study reinforces the extensive evidence showing the potential of Chemomab's CCL24-neutralizing antibody, CM-101, to interrupt the biological processes driving PSC disease progression and severity. The study, "Machine Learning Identifies Key Proteins in Primary Sclerosing Cholangitis Progression and Links High CCL24 to Cirrhosis"1 has been published in the current online version of the peer-reviewed International Journal of Molecular Science.T ...Notably, the analysis showed that enrichment for PSC-related biological pathways was associated with high levels of CCL24 and that patients with cirrhosis had higher levels of CCL24, providing further evidence for the role of CCL24 in disease progression and severity. The authors also noted that the biomarkers identified in this study have significant translational importance, offering potential advancements in the monitoring of disease progression in clinical settings. "These proteomic analyses add to the large body of data showing that CCL24 is a major driver of PSC disease progression and severity...."We look forward to our CM-101 PSC Phase 2 topline data readout in the coming weeks, which has the potential to provide the first significant clinical proof-of-concept of CM-101's therapeutic activity in this lethal disease with no FDA approved therapies."

07:07 EDT Silk Road Medical to be acquired by Boston Scientific for $27.50 per share - Silk Road Medical (SILK) entered into a definitive agreement to be acquired by Boston Scientific Corporation (BSX) for $27.50 in cash per share, representing an equity value of approximately $1.26 billion. The per share price represents an approximate 38% premium to the volume-weighted average share price of Silk Road Medical's common stock over the past 60 days. The board of directors of Silk Road has unanimously approved the transaction and recommend that Silk Road stockholders adopt the merger agreement. The transaction is expected to close in the second half of 2024, subject to the satisfaction of customary closing conditions, including approval by Silk Road's stockholders and applicable regulatory approvals. Upon the completion of the transaction, Silk Road will become a wholly-owned subsidiary of Boston Scientific.

07:05 EDT FDA places partial clinical hold on certain Zentalis' studies of azenosertib - Zentalis Pharmaceuticals announced that the U.S. Food and Drug Administration FDA has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 DENALI study in platinum-resistant ovarian cancer PROC and the Phase 2 ZN-c3-004 TETON study in uterine serous carcinoma USC . This action follows two recent deaths due to presumed sepsis in the DENALI study. "Patient safety is our top priority and any deaths that occur in the setting of clinical trials are unfortunate. We are working closely with the FDA to resolve this partial clinical hold as quickly as possible," said Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis. "Over 500 patients have been treated with azenosertib monotherapy to date, and we believe that our data indicate a favorable therapeutic index that could potentially offer meaningful benefits to women facing PROC and USC. We have completed enrollment for Cohort 1b of the DENALI study, where we've enrolled more than a hundred patients, further demonstrating the support we've seen for having a novel oral therapy like azenosertib. We look forward to sharing these results along with overall efficacy and safety data from DENALI Cohort 1b later this year."

07:04 EDT Immunocore announces randomization of first patient in Phase 3 brenetafusp trial - Immunocore Holdings announces randomization of the first patient in the PRISM-MEL-301 trial, assessing the efficacy and safety of brenetafusp, in combination with nivolumab, in first-line advanced or metastatic cutaneous melanoma. The Phase 3 trial will randomize HLA-A*02:01 positive patients with first-line, advanced or metastatic cutaneous melanoma to brenetafusp + nivolumab versus a control arm of either nivolumab or nivolumab + relatlimab, depending on country. Bristol Myers Squibb will provide nivolumab. The Company has shared the cutaneous melanoma Phase 1 data during an oral presentation at the 2024 American Society of Oncology Annual Meeting on 31 May. The data showed that brenetafusp was well tolerated as monotherapy and in combination with anti-PD1, and demonstrated promising monotherapy clinical activity, including disease control rate, progression free survival, and circulating tumor DNA molecular response. Brenetafusp is the first PRAME x CD3 ImmTAC bispecific protein targeting an HLA-A*02:01 PRAME antigen. The Company is continuing to enroll patients into a Phase 1/2 trial in monotherapy and combination arms across multiple tumor types, including three expansion arms for patients with advanced ovarian, non-small cell lung, and endometrial cancers.

07:03 EDT Ionis Pharma expands donidalorsen licensing agreement in Asia Pacific - Ionis Pharmaceuticals has entered into a license agreement with Otsuka Pharmaceutical under which Otsuka obtains exclusive rights across the Asia-Pacific region for donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema or HAE. Ionis will maintain primary responsibility for the development of donidalorsen, while Otsuka will be responsible for territory-specific development, regulatory filings and commercialization in the Asia-Pacific region and Europe. Ionis plans to file a New Drug Application with the FDA this year, and will independently launch donidalorsen in the U.S., if approved. Ionis and Otsuka previously announced a licensing agreement for donidalorsen in Europe, and Otsuka is also preparing to submit a Marketing Authorization Application to the European Medicines Agency this year. Under the terms of the Asia-Pacific agreement, Ionis will receive a $20M upfront payment and milestone payments based on achievement of regulatory and sales targets. Ionis is also eligible to earn tiered royalties, with similar economic terms to the previous agreement for Europe. Ionis recently reported positive results from two Phase 3 studies, presented at the 2024 European Academy of Allergy and Clinical Immunology Annual Congress in Valencia, Spain and published in The New England Journal of Medicine.

07:01 EDT Orthofix appoints McPherron as President of Global Operations, Quality - Orthofix Medical (OFIX) announced the appointment of Aviva McPherron as President of Global Operations and Quality. As a member of the Executive Leadership Team, McPherron will oversee strategy for the company's operations, manufacturing, regulatory, clinical, and quality teams. McPherron joins Orthofix from Globus Medical (GMED) where she served as Senior Vice President, Clinical Services and Integration and was responsible for strategic initiatives to drive growth and enhance profitability.

06:59 EDT KKR-led consortium to invest $1.3B in ST Telemedia Global Data Centres - A KKR-led consortium of KKR and Singtel will invest $1.3B in ST Telemedia Global Data Centres - STT GDC -, a data centre colocation services provider. This transaction marks the largest digital infrastructure investment in Southeast Asia to date in 2024. The transaction comprises an initial S$1.75B - ~$1.3B - investment by the Consortium via Redeemable Preference Shares with detachable warrants. Upon exercise of the warrants in full, the Consortium will invest an additional S$1.24B - ~$920M -. The proceeds of the investment will be used to further advance STT GDC's position in the markets it operates in, and to support its continuing international expansion and growth plans through organic and inorganic strategies. Following the transaction, ST Telemedia continues to be the majority shareholder of STT GDC. KKR is making this investment from its Asia Pacific Infrastructure Investors II Fund.

06:47 EDT Golden Minerals CEO Warren Rehn resigns, EVP Pablo Castanos succeeds - Golden Minerals announced the retirement of CEO and President, Warren Rehn, effective immediately. Rehn joined the company in 2012 as VP Exploration and was promoted to President in spring of 2015 and to CEO in September 2015. Rehn has also resigned his position as a Director of the company. Rehn will continue to support the Company, advising on exploration and technical activities as a consultant. Pablo Castanos, currently EVP, has been elected CEO and President of the company and appointed to serve as a Director. Castanos joined the company in July of 2023 and has been preparing for the role of President and CEO pending Rehn's retirement. Castanos previously worked for Golden Minerals as VP and Director of Ccorporate Affairs from 2009 to 2013 before leaving to work for Goldcorp as director of environmental compliance and as vice president corporate social responsibility. Between 2016 and 2023, Castanos acted as a private investor in real estate development and construction.

06:36 EDT Pluri subsidiary Ever After Foods secures $10M strategic investment - Pluri announced strategic investments in Pluri's subsidiary, Ever After Foods, which offers a technology platform to produce cultivated food with cost-efficient scalability. Ever After Foods is Pluri's majority-owned joint venture with Israeli food giant Tnuva Food-Tech Incubator, and has exclusive licensing rights to use Pluri's technology and intellectual property to develop, manufacture and commercialize cultivated meat. Developing the B2B version of its proprietary technology system, Ever After Foods has demonstrated the natural production of muscle and fat tissues for various animal cells. With this new investment, Pluri has extended the license field granted to Ever After Foods to include cultivated fish.

06:33 EDT GoldMining announces assay results from drilling program at Sao Jorge project - GoldMining announced assay results from the first drill hole of its recently announced drilling program at the Company's 100% owned Sao Jorge Project on the Tapajos Gold district, Para State, Brazil. The program consists of approximately 1,000 metres of total proposed diamond core drilling and 3,000 m of power auger drilling. The objectives of the program include, among other things, to complete confirmatory drilling within and near the margins of the existing Sao Jorge gold deposit, and test a reinterpretation of the structural controls on high-grade mineralization. Assay results for the first diamond drill hole have been received and are reported in this release. Drill Hole SJD-120-24 highlights include: 163 m at 1.02 grams per tonne gold from 44 m downhole depth, including higher-grade intersections: 20 m at 1.37 g/t Au from 44 m depth; 37 m at 2.26 g/t Au from 95 m depth; 11 m at 1.00 g/t Au from 148 m depth; 13 m at 1.35 g/t Au from 166 m depth; and 12 m at 1.15 g/t Au from 195 m depth. Tim Smith, Vice President of Exploration, commented: "We are pleased to announce the results from the first drilling at Sao Jorge in more than a decade. The results from this first drill hole are strong and we believe help demonstrate an extensive corridor of mineralization consisting of multiple intercepts of broad gold mineralization. These include some narrower higher-grade zones. Oriented diamond core drilling has successfully confirmed our thesis for the structural controls on mineralization within the deposit, which was the first objective of our multi-pronged drilling program. We expect that the improved geological model based on these intercepts will provide greater confidence in future mineral resource estimation. Additionally, we have commenced the auger drilling component of the program and forward to providing additional updates."

06:31 EDT KalVista submits New Drug Application to FDA for sebetralstat - KalVista Pharmaceuticals announced the submission of a New Drug Application for U.S. FDA review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema attacks in adults and pediatric patients aged 12 years and older.

06:19 EDT Infosys annnounces launch of AI-amplified marketing services Infosys Aster - Infosys announced the launch of Infosys Aster, a set of AI-amplified marketing services, solutions and platforms that deliver engaging brand experiences, enhanced marketing efficiency, and accelerated effectiveness for business growth. It drives AI-led transformation of marketing with integrated, real-time view across customers, brands and channels, enabling companies to increase ROI from marketing. With creative services, experience design, digital commerce, MarTech orchestration, performance marketing and marketing operations, Infosys Aster brings agility to the marketing value chain for B2B and B2C brands. With Infosys Aster, global brands have realized up to 50% increase in repeat buyers, 30% improvement in the cost of marketing operations, and 40% increase in sales.

06:06 EDT Nokia expands collaboration with Google Cloud - Nokia (NOK) announced that it is expanding its collaboration with Google Cloud (GOOG, GOOGL) to give developers around the world the network software tools they need to create innovative new 5G enterprise and consumer applications faster for their customers. Now, Nokia's Network as Code platform with developer portal will run on Google Cloud, enriching the developer experience via Google Cloud data and generative AI solutions and capabilities, including Vertex AI and Gemini 1.5 Pro. This will enable developers to easily consume AI in their applications and improve productivity with coding assistance agents. The companies will target industry use cases to promote with the Google Cloud developer community, starting with healthcare to deliver better, safer customer experiences. Google Cloud's expansive developer community, covering all major industries and geographies, will benefit by having access to standardized 5G network capabilities around the world, exposed through Nokia's Network as Code platform with developer portal, giving them the technical tools required to quickly create new applications for their customers.

06:04 EDT Greenwave Technology regains full compliance with Nasdaq listing standards - Greenwave Technology received formal notice from Nasdaq that the company has evidenced compliance for continued listing on the Nasdaq Capital Market. Accordingly, the listing matter has been closed.

06:03 EDT Comscore and Kochava partner in new cross-screen measurement solution - Comscore and Kochava, a real-time data solutions company for omnichannel attribution and measurement, announced a new cross-screen performance media measurement solution to better understand how linear TV ad campaigns meaningfully impact both online and offline behaviors. By combining Comscore's Exact Commercial Ratings data and Kochava's advanced marketing mix modeling, Comscore and Kochava can now deliver outcomes measurement for key metrics such as mobile app activity, website activity, merchant-level purchase data, episodic tune-ins, etc. This new capability aims to bring further clarity to cross-screen measurement by determining which behaviors can be attributed directly to specific linear ad placements.

05:58 EDT Amdocs collaborates with Google Cloud for real-time data insights - Amdocs (DOX) announced a collaboration with Google Cloud (GOOG, GOOGL) to accelerate successful data transformations for communications service providers and better provide impactful real-time business insights. Amdocs' AI and Data Platform (previously DataOne) now leverages Google Cloud's unified AI-ready data platform to help CSPs better leverage data to make business decisions. Further, the platform also uses Google Cloud Architecture Framework to create a layered and service-based architecture that leverages best practices for operational excellence, reliability, cost optimization, performance optimization, security, privacy and compliance. The result is a unified, telecom-specific real-time data source that integrates information from various systems across the business. By combining Amdocs' data insights with Google Cloud's AI capabilities and BigQuery's data assets, service providers can unlock new opportunities for innovation and efficiency, transforming customer experiences, business operations and revenue performance, helping CSPs evolve into true AI-driven service providers.

05:36 EDT AstraZeneca reports CAPItello-290 Phase 3 trial did not meet primary endpoints - The CAPItello-290 Phase 3 trial for Truqap in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative breast cancer, or TNBC, did not meet the dual primary endpoints of improvement in overall survival, or OS, versus paclitaxel in combination with placebo in either the overall trial population or in a subgroup of patients with tumours harbouring specific biomarker alterations, AstraZeneca announced. Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "We are committed to advancing science for patients in some of the most challenging cancers, including this heterogeneous subtype of breast cancer. While we are disappointed in the CAPItello-290 outcome, these results will further our understanding of the role of the PI3K/AKT pathway in breast cancer as we continue our clinical research across the Truqap clinical development programme and across our pipeline." The company added: "The safety profile of Truqap in combination with paclitaxel in CAPItello-290 was broadly consistent with the known safety profile of each medicine with no new safety concerns identified. Data will be shared in due course. Truqap is currently being evaluated in Phase III trials for the treatment of breast cancer (CAPItello-292) and prostate cancer (CAPItello-280 and CAPItello-281) in combination with established treatments."